<DOC>
	<DOCNO>NCT00795756</DOCNO>
	<brief_summary>The aim clinical study adult ALL compare risk category ( 1 ) feasibility two different CNS prophylaxis regimen ( 2 ) overall disease-free survival relation achievement early MRD negative status follow consolidation lineage-targeted methotrexate infusion disease-specific therapeutic element , without application allogeneic autologous SCT depend risk class MRD study result . In multicentric prospective pilot randomize phase II trial CNS prophylaxis , patient receive induction/consolidation therapy incorporate lineage-targeted high-dose methotrexate plus drug ( additional imatinib Ph/BCR-ABL+ ALL ) , achievement early negative MRD status . The MRD study support risk/MRD-oriented final consolidation phase .</brief_summary>
	<brief_title>Intrathecal DepoCyte Lineage-targeted Minimal Residual Disease-oriented Therapy Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>A ) Risk Classification Newly diagnose patient hierarchically cluster high , high standard risk case ( VHR , HR , SR ) use international risk criterion modify accord NILG : A1 ) VHR ( criterium ) : B-precursor : WBC count &gt; 100x109/L ; adverse cytogenetics/molecular biology ( 9 ; 22 ) /BCR-ABL , ( 4 ; 11 ) /MLL rearrangement 11q23 , +8 , -7 , del6q , ( 8 ; 14 ) , low hypodiploidy 30-39 chromosome , near triploidy 60-78 chromosome , complex &gt; 5 unrelated anomaly . T-precursor : WBC count &gt; 100x109/L ; early/late non-cortical immunophenotype ( CD1a- ) ; adverse cytogenetics/molecular biology ( ) . A2 ) HR ( criterium , VHR exclude ) : B-precursor : WBC count &gt; 30x109/L ; pro-B immunophenotype ; complete remission cycle 2 . T-precursor : complete remission cycle 2 . A3 ) SR ( criterion , VHR/HR exclude ) : B-precursor : WBC count &lt; 30x109/L ; T-precursor : WBC count &lt; 100x109/L ; cortical immunophenotype ( CD1a+ ) . B ) CNS Prophylaxis Stratification randomisation 1. immunophenotype , i.e . B-precursor vs. T-precursor 2. risk class , i.e . SR vs. non-SR ( use know factor ) Randomisation : intrathecal ( IT ) CNS prophylaxis standard triple therapy ( TIT , 12 total injection ) vs. DepoCyte ( 6-8 total injection disease subset ) . Cranial irradiation omit arm , patient receive chemotherapy program include CNS-crossing agent . C ) Induction/Early Consolidation MRD Study Randomised patient receive homogeneous induction/early consolidation chemotherapy , include subset-specific element B-precursor ALL ( 3x targeted-infusion methotrexate 2.5 g/m2 ) , T-precursor ALL ( 3x targeted-infusion methotrexate 5 g/m2 ) , age &gt; 55 year ( methotrexate reduce 1.5 g/m2 ) , Ph/BCR-ABL+ ALL ( imatinib , reduced-intensity chemotherapy ) , radiation therapy ( LL ) . Patients CR cycle 1-2 study . For CR evaluation bone marrow check day 28 and/or 56 . Consolidation cycle administer 21-28 day interval Concurrent MRD analysis perform four timepoints ( week 4 , 10 , 16 22 induction/consolidation ) , optimize risk classification support risk/MRD-oriented therapy : C1 ) MRD negative ( M-NEG ) : negative MRD study ( &lt; 10-4 timepoints # 2 # 3 , negative timepoint # 4 ) C2 ) MRD positive ( M-POS ) : positive MRD study ( &gt; 10-4 timepoints # 2 # 3 , positive timepoint # 4 ) D ) MRD/Risk-Oriented Final Therapy D1 ) VHR patient candidate early allogeneic SCT ( related/unrelated donor/cord blood ; ablative/non-ablative conditioning accord current protocols/guidelines ) CR , regardless MRD study result . D2 ) M-POS well HR patient unknown MRD allocate allogeneic SCT MRD timepoint 2 ( M-POS &gt; 10-4 ) MRD timepoint 4 ( others ) . When allogeneic SCT possible , patient complete consolidation receive autologous-type SCT follow maintenance . D3 ) M-NEG well SR patient unknown MRD allocate maintenance therapy . Age-limited therapeutic procedure : Patients age &gt; 55 year treat age-adapted therapy , indicate include SCT program whenever possible accord performance status comorbidity .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neoplasm , Residual</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Age 1865 year . Diagnosis untreated ALL B/Tprecursor phenotype Bcell lymphoblastic lymphoma ( BLL ) , either de novo secondary chemoradiotherapy cancer . Full cytological , cytochemical , cytogenetic immunobiological disease characterization revise FAB , EGIL WHO criteria . Bone marrow peripheral blood sampling ( ALL ) biopsy specimen ( LL ) MRD study . ECOG performance status 02 reversible ECOG 3 score follow intensive care complication . Signed informed consent . Diagnosis BALL ( FAB L3 ALL/Burkitt 's leukemia lymphoma ) TLL ( Tcell lymphoblastic lymphoma ) . Down 's syndrome . Preexisting , uncontrolled pathology cardiac disease ( congestive/ischemic , acute myocardial infarction within past 3 month , untreatable arrythmias , NYHA class III IV ) , severe liver disease serum bilirubin &gt; 3 mg/dL and/or ALT &gt; 3 x upper normal limit ( unless attributable ALL/LL ) , kidney function impairment serum creatinine &gt; 2 mg/dL ( unless attributable ALL/LL ) , severe neurological psychiatric disorder impair patient 's ability understand sign inform consent , cope intend treatment plan . Known HIV positive serology . Other active hematological nonhematological cancer life expectancy &lt; 1 year . Pregnancy ( fertile woman advise become pregnant treatment ; male patient adopt contraceptive method ) , unless therapeutic aborption/early discharge carry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Adults</keyword>
	<keyword>Central nervous system prophylaxis</keyword>
	<keyword>Minimal residual disease</keyword>
</DOC>